Medicus Pharma Ltd (MDCX)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Medicus Pharma Ltd Stock (MDCX) Company Profile

Medicus Pharma Ltd

Healthcare (1170)

610-540-7515

300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN

Nächster Verdiensttermin

Neueste SEC-Einreichungen

MDCX's Discussions on Twitter

Vergleichen Sie MDCX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MDCX Medicus Pharma Ltd	2.63	83.13M	0	-11.73M	-10.37M	-1.3826
LLY Lilly Eli Co	751.86	651.06B	49.00B	11.11B	-1.27B	12.29
JNJ Johnson Johnson	154.93	368.73B	89.33B	21.81B	18.57B	8.99
ABBV Abbvie Inc	187.28	328.06B	57.37B	4.20B	15.39B	2.35
NVS Novartis Ag Adr	115.90	223.60B	53.22B	12.86B	14.85B	6.39
NVO Novo Nordisk Adr	71.32	312.99B	43.59B	15.04B	10.74B	3.3766

Medicus Pharma Ltd Aktie (MDCX) Neueste Nachrichten

Finanzdaten der Medicus Pharma Ltd-Aktie (MDCX)

Medicus Pharma Ltd (MDCX)

Medicus Pharma Ltd Stock (MDCX) Company Profile

Vergleichen Sie MDCX mit anderen Aktien

Medicus Pharma Ltd Aktie (MDCX) Neueste Nachrichten

Medicus Pharma completes $7 million public offering - Investing.com

Medicus Pharma Secures $7 Million for Cancer Treatment Trials - TipRanks

Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering - Newsfile

Medicus Pharma closes $7M public offering - Proactive financial news

Medicus Pharma prices $7 million share offering - MSN

Health Sector Experiences Mixed Fortunes As Trials And Stock Moves Shake Up Market - Finimize

Biotech Stocks Plummet As Public Offerings Shake Market - Finimize

Sector Update: Health Care - marketscreener.com

Form 424B4 Medicus Pharma Ltd. - StreetInsider

Small cap wrap: ReconAfrica, Charbone Hydrogen, Medicus Pharma.... - Proactive financial news

Medicus Pharma Prices $7 Million Public Offering; Shares Fall - marketscreener.com

Medicus Pharma unveils pricing of $7M public offering - Proactive financial news

Medicus Pharma’s (MDCX) Buy Rating Reaffirmed at D. Boral Capital - Defense World

Medicus Pharma (NASDAQ:MDCX) Upgraded at Wall Street Zen - Defense World

Medicus Pharma Ltd. Launches $7 Million Public Offering to Advance Cancer Treatment Trials - TipRanks

Medicus Pharma Secures $7M Funding to Advance Revolutionary Skin Cancer Patch Through Phase 2 Trials - Stock Titan

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering - Newsfile

Medicus Pharma Files For Resale From Time To Time Of Up To 3.7 Mln Common Shares - marketscreener.com

Medicus Pharma begins UAE cancer trial expansion – ICYMI - Proactive financial news

Medicus Pharma’s (MDCX) Buy Rating Reiterated at D. Boral Capital - Defense World

OpenAI’s $6.5B Deal With Jony Ive Hints at a Post-iPhone AI Era - The Globe and Mail

Medicus Pharma receives UAE approval to begin Phase 2 study for non-invasive BCC treatment - Proactive financial news

Small cap wrap: Nextech3D.ai, Medicus Pharma, Synchronoss, ReconAfrica... - Proactive financial news

Medicus Pharma Ltd. Gains UAE Approval for Phase 2 Basal Cell Carcinoma Study - TipRanks

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates Department of Health to Commence Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin - Malay Mail

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) - Newsfile

New Non-Invasive Skin Cancer Treatment Advances to Phase 2 in UAE After 46% Success Rate - Stock Titan

Medicus Pharma gets UAE approval for Phase 2 study for skin cancer therapy - Proactive financial news

Major Shareholder Sells Off Huge Chunk of Medicus Pharma Stock! - TipRanks

This Magnificent Stock Is Up 370% From Its 2022 Low -- 2 Reasons to Buy It Now, and 1 Reason to Steer Clear - The Globe and Mail

Chart of the DayJuly Wheat - The Globe and Mail

Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money - The Globe and Mail

Is Google Stock Worth Buying In 2025? - The Globe and Mail

Medicus Pharma (NASDAQ:MDCX) Price Target Raised to $27.00 at D. Boral Capital - Defense World

Pre-market Movers: CNSP, XLO, PLRZ, SGMO... - RTTNews

Medicus Pharma Ltd. SEC 10-Q Report - TradingView

Medicus Pharma price target raised to $27 from $14 at D. Boral Capital - TipRanks

Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio - Benzinga

Medicus Pharma secures $15 million funding option - MSN

Medicus Pharma stock target lifted to $27 on Antev acquisition By Investing.com - Investing.com Nigeria

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga

Medicus Pharma stock target lifted to $27 on Antev acquisition - Investing.com Australia

Certain Common Shares of Medicus Pharma Ltd. are subject to a Lock-Up Agreement Ending on 12-MAY-2025. - marketscreener.com

Certain Options of Medicus Pharma Ltd. are subject to a Lock-Up Agreement Ending on 12-MAY-2025. - marketscreener.com

Maxim Group Upgrades Medicus Pharma (CVE:MDC) to “Strong-Buy” - Defense World

Medicus Pharma to acquire Antev, advancing opportunity in prostate health solutions - Proactive financial news

Medicus Pharma to acquire Antev for $75M in share exchange transaction - MSN

Medicus Pharma signs letter of intent to buy British biotech company - The Business Journals

Medicus Pharma to acquire Antev in strategic biotech deal By Investing.com - Investing.com South Africa

Medicus Pharma to acquire Antev in strategic biotech deal - Investing.com Australia

Small cap wrap: Medicus Pharma, Arizona Gold & Silver, Plug Power... - Proactive financial news

Finanzdaten der Medicus Pharma Ltd-Aktie (MDCX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie MDCX